ClinicalTrials.Veeva

Menu
M

Medisch Spectrum Twente | Thorax Centrum Twente - Foundation Cardiovascular Research and Education Enschede

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

prednisone
doxorubicin hydrochloride
vincristine sulfate
cisplatin
cyclophosphamide
Lenalidomide
Bococizumab
Vemurafenib
Upadacitinib
vinblastine sulfate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

31 of 221 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the...

Enrolling
ST-elevation Myocardial Infarction (STEMI)
Drug: Placebo
Drug: zalunfiban

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: rituximab
Drug: placebo

This randomized controlled trial will outline the advantages and disadvantages of the subcutaneous implantable cardioverter defibrillator (ICD) compa...

Active, not recruiting
Ventricular Arrhythmias
Device: Implantation of subcutaneous ICD
Device: Implantation of transvenous ICD

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) an...

Active, not recruiting
Axial Spondyloarthritis
Drug: Placebo
Drug: Filgotinib

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: LY3537982

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts abou...

Active, not recruiting
Lipoprotein Disorder
Drug: Placebo
Drug: LY3819469

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Cyclophosphamide
Locations recently updated

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the po...

Active, not recruiting
Stroke
Device: WATCHMAN LAAC Device Implant
Drug: Single Antiplatelet Therapy or No Therapy (Control)

This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in p...

Enrolling
Hemorrhage
Invasive Procedure
Drug: Bentracimab (PB2452) Infusion

The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary emboli...

Enrolling
Venous Thromboembolism
Pulmonary Embolism
Drug: Rivaroxaban
Drug: Placebo

Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Ph...

Invitation-only
Ischemic Heart Disease
Coronary Artery Disease
Device: Philips SyncVision system with Philips pressure wires
Procedure: standard of care angiographically-guided PCI

Background: Intracerebral hemorrhage (ICH) accounts for 16-19% of all strokes in Western Europe and contributes profoundly to mortality and disabilit...

Enrolling
Minimally Invasive Surgical Procedures
Endoscopic Surgical Procedures
Device: Minimally invasive endoscopy-guided surgery
Locations recently updated

The objective of the study is to assess the stent stability and durability as well as the seal of the stent graft during the cardiac cycle and over t...

Enrolling
Vascular Aneurysm
Diagnostic Test: ECG-gated CTAs

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

The goal of this diagnostic randomised clinical trial is to determine, in glioblastoma patients with diagnostic uncertainty between pseudoprogression...

Begins enrollment this month
Glioblastoma
Radionecrosis of Brain
Other: Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan

Trial sponsors

E
R
Erasmus University logo
M
Maastricht University Medical Centre (MUMC) logo
U
Netherlands Cancer Institute (NKI) logo
U
Abbott logo
Boston Scientific logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems